Untersuchungen zum Mechanismus der Atemwirkung des Anaphylatoxins

Bodammer, G.

doi:10.1007/bf00545004

Cited by 11 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacological antagonists as well as the cycloox ygenase inhibitor indomethacin were employed to de termine if histamine, acetylcholine and arachidonate metabolites played a role in C5a-induced broncho constriction. The results of our studies confirm those of Bodammer and Vogt [5,6] suggesting that hista mine and cyclooxygenase products are mediators of C5a-induced bronchoconstriction. However, our studies provide additional evidence indicating that peptidoleukotrienes are not important mediators of the C5a-induced decrease in dynamic lung compli ance and increase in pulmonary resistance in the guinea pig.…”

Section: Introductionsupporting

confidence: 81%

“…These results are in contrast to the results of Bodammer [6] who in dicated that the antihistamine tripelennamine, com bined with atropine (2 mg/kg), prevented any C5a-induced bronchoconstriction in urethane-anesthetized guinea pigs whereas tripelennamine alone merely re duced the response. The difference in the studies may possibly be accounted for by the higher dose of atro pine utilized by Bodammer.…”

Section: Discussioncontrasting

confidence: 56%

“…Studies of Bodammer and Vogt [5,6] had suggested that histamine may be involved in C5a-induced bron choconstriction. Thus, we closely examined the effect of pyrilamine on the time course of the C5a-induced bronchoconstriction.…”

Section: Discussionmentioning

confidence: 99%

“…The more recent studies of Bodammer and Vogt [5] and Bodammer [6] measured C5a-induced changes in tracheal air flow and transpulmonary pressure using doses of hog anaphylatoxin from 25-1,500 /xg/kg. Bronchospasm was rated on a + 1 to + 3 scale in either unanesthetized or urethaneanesthetized animals.…”

Section: Discussionmentioning

confidence: 99%

“…In the studies of Bodammer and Vogt [5,6], calcu lations of pulmonary resistance and dynamic lung compliance were not done and only maximum effects were evaluated qualitatively. In our studies, the doserelated response to C5a is monitored quantitatively over time without the complication of changes in re spiratory rate.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Mediators of C5a-Induced Bronchoconstriction in the Guinea Pig

Regal

Bell²

1987

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The effect of intravenous injection of C5a on pulmonary resistance and dynamic lung compliance was determined in anesthetized, artificially respirated guinea pigs. A mixture of C5a plus C5a_{des arg} was purified from yeast-activated guinea pig serum and is referred to as C5a. Intravenous injection of C5a caused a dose-related bronchoconstriction as evidenced by a decrease in compliance and increase in resistance. Conversion of the C5a in the mixture to C5a_{des arg} by carboxypeptidase B digestion did not significantly alter the magnitude of the bronchoconstriction. Pharmacological antagonists were employed to determine if histamine, acetylcholine or products of the arachidonate metabolism were mediators of C5a-induced bronchoconstriction. The histamine H₁ antagonist pyrilamine inhibited the C5a-induced bronchoconstriction, suggesting the involvement of histamine. The cholinergic receptor antagonist atropine in combination with pyrilamine caused an inhibition of the C5a-induced increase in resistance but not compliance, suggesting acetylcholine does not play a major role in C5a-induced bronchoconstriction beyond its known role in participating in histamine-induced bronchoconstriction. Involvement of arachidonate metabolites was suggested by the ability of the cyclooxygenase inhibitor, indomethacin, to prevent the C5a-induced bronchoconstriction. Because indomethacin also caused a delay in the leukotriene C₄ (LTC₄)-induced bronchoconstriction, the participation of peptidoleukotrienes in the C5a-induced bronchoconstriction could not be ruled out. The leukotriene antagonists FPL 55712 and L-649,923 were evaluated for their specificity in inhibiting LTC₄-induced bronchoconstriction. FPL 55712 was nonselective since it inhibited prostaglandin D₂ and histamine-induced bronchoconstriction as well as LTC₄-induced bronchoconstriction. L-649,923 inhibited only the LTC₄-induced bronchoconstriction and was without effect on the C5a-induced bronchoconstriction, suggesting that peptidoleukotrienes are not important mediators of C5a-induced bronchoconstriction. Using radioimmunoassay, the change in peptidoleukotriene levels detected in plasma during C5a-induced bronchoconstriction was not significantly different from 0. Thus, these studies have quantitated the C5a-induced decrease in dynamic lung compliance and increase in pulmonary resistance and suggest that histamine and cyclooxygenase products, but not peptidoleukotrienes, play a major role in C5a-induced bronchoconstriction.

show abstract

Section: Introductionsupporting

confidence: 81%

Section: Discussioncontrasting

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations